688321 微芯生物
已收盘 08-26 15:00:00
资讯
新帖
简况
【机构调研记录】景顺长城基金调研晶升股份、微芯生物等4只个股(附名单)
证券之星 · 08:05
【机构调研记录】景顺长城基金调研晶升股份、微芯生物等4只个股(附名单)
微芯生物:8月20日进行路演,东吴证券、长城基金等多家机构参与
证券之星 · 08-23 17:22
微芯生物:8月20日进行路演,东吴证券、长城基金等多家机构参与
【机构调研记录】金鹰基金调研微芯生物
证券之星 · 08-21
【机构调研记录】金鹰基金调研微芯生物
【机构调研记录】财通基金调研微芯生物
证券之星 · 08-21
【机构调研记录】财通基金调研微芯生物
【机构调研记录】西部利得基金调研中宠股份、微芯生物等4只个股(附名单)
证券之星 · 08-21
【机构调研记录】西部利得基金调研中宠股份、微芯生物等4只个股(附名单)
【机构调研记录】浙商基金调研图南股份、微芯生物等3只个股(附名单)
证券之星 · 08-21
【机构调研记录】浙商基金调研图南股份、微芯生物等3只个股(附名单)
【机构调研记录】汇丰晋信基金调研微芯生物、地铁设计等3只个股(附名单)
证券之星 · 08-21
【机构调研记录】汇丰晋信基金调研微芯生物、地铁设计等3只个股(附名单)
【机构调研记录】易米基金调研海泰新光、微芯生物
证券之星 · 08-21
【机构调研记录】易米基金调研海泰新光、微芯生物
【机构调研记录】博远基金调研微芯生物
证券之星 · 08-21
【机构调研记录】博远基金调研微芯生物
【机构调研记录】华夏基金调研微芯生物、思瑞浦等8只个股(附名单)
证券之星 · 08-21
【机构调研记录】华夏基金调研微芯生物、思瑞浦等8只个股(附名单)
【机构调研记录】前海联合调研微芯生物
证券之星 · 08-21
【机构调研记录】前海联合调研微芯生物
【机构调研记录】前海开源基金调研海泰新光、微芯生物等3只个股(附名单)
证券之星 · 08-21
【机构调研记录】前海开源基金调研海泰新光、微芯生物等3只个股(附名单)
微芯生物:8月19日组织现场参观活动,包括知名机构华银精治的多家机构参与
证券之星 · 08-20
微芯生物:8月19日组织现场参观活动,包括知名机构华银精治的多家机构参与
微芯生物(688321):西达本胺新适应症持续开拓 西格列他钠进入收获期
长城证券股份有... · 08-20
微芯生物(688321):西达本胺新适应症持续开拓 西格列他钠进入收获期
非酒精性脂肪性肝炎(NASH)概念盘中跳水,微芯生物跌3.54%
自选股智能写手 · 08-20
非酒精性脂肪性肝炎(NASH)概念盘中跳水,微芯生物跌3.54%
太平洋:给予微芯生物买入评级
证券之星 · 08-19
太平洋:给予微芯生物买入评级
华福证券给予微芯生物买入评级
每日经济新闻 · 08-18
华福证券给予微芯生物买入评级
华福证券:给予微芯生物买入评级,目标价位33.92元
证券之星 · 08-18
华福证券:给予微芯生物买入评级,目标价位33.92元
微芯生物(688321)2024年中报简析:增收不增利
证券之星 · 08-17
微芯生物(688321)2024年中报简析:增收不增利
微芯生物(688321)6月30日股东户数1.95万户,较上期减少7.78%
证券之星 · 08-16
微芯生物(688321)6月30日股东户数1.95万户,较上期减少7.78%
公司概况
公司名称:
深圳微芯生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2019-08-12
主营业务:
深圳微芯生物科技股份有限公司的主营业务为药物技术开发、相关成果商业应用,主要产品均为自主研究发现与开发的新分子实体且作用机制新颖的原创新药。公司获得2020中国医药工业信息中心颁发的“中国医药新锐创新力量”奖;2020年10月,公司获 得“2020中国化学制药行业成长型优秀企业品牌”与“2020中国化学制药行业抗肿瘤和免疫调节剂类优秀产品品牌”两个奖项。
发行价格:
20.43
{"stockData":{"symbol":"688321","market":"SH","secType":"STK","nameCN":"微芯生物","latestPrice":17.03,"timestamp":1724655600000,"preClose":16.78,"halted":0,"volume":1587163,"delay":0,"floatShares":408000000,"shares":408000000,"eps":-0.2645,"marketStatus":"已收盘","marketStatusCode":5,"change":0.25,"latestTime":"08-26 15:00:00","open":16.64,"high":17.25,"low":16.64,"amount":27037300,"amplitude":0.0364,"askPrice":17.05,"askSize":10,"bidPrice":17.03,"bidSize":9,"shortable":0,"etf":0,"ttmEps":-0.2645,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724722200000},"adr":0,"adjPreClose":16.78,"symbolType":"stock_kcb","openAndCloseTimeList":[[1724635800000,1724643000000],[1724648400000,1724655600000]],"highLimit":18.46,"lowLimit":15.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407795845,"pbRate":4.54,"roa":"--","roe":"--","epsLYR":0.2176,"committee":0.013721,"marketValue":6945000000,"floatMarketCap":6945000000,"peRate":-64.385635,"changeRate":0.0149,"turnoverRate":0.0039,"status":0,"afterMarket":{"amount":0,"volume":0,"close":17.03,"buyVolume":0,"sellVolume":0,"time":1724657637153,"indexStatus":"已收盘 08-26 15:30:00","preClose":16.78}},"requestUrl":"/m/hq/s/688321/wiki","defaultTab":"wiki","newsList":[{"id":"2462983529","title":"【机构调研记录】景顺长城基金调研晶升股份、微芯生物等4只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2462983529","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462983529?lang=zh_cn&edition=full","pubTime":"2024-08-26 08:05","pubTimestamp":1724630719,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及8月23日披露的机构调研信息,景顺长城基金近期对4家上市公司进行了调研,相关名单如下:1)晶升股份 个股亮点:公司是一家半导体专用设备供应商,主要从事晶体生长设备的研发、生产和销售。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082600001502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688478","BK0239","688321","BK0251"],"gpt_icon":0},{"id":"2461653550","title":"微芯生物:8月20日进行路演,东吴证券、长城基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2461653550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461653550?lang=zh_cn&edition=full","pubTime":"2024-08-23 17:22","pubTimestamp":1724404943,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年8月23日微芯生物发布公告称公司于2024年8月20日进行路演,东吴证券、长城基金、泰康资产、国盛证券、国泰君安证券、大成基金、景顺长城基金、国泰基金、汇添富基金、红土创新基金、惠通基金参与。西达本胺已在 PTCL 广泛应用,同时西达本胺的安全性良好可控,多种不同机 制的联合治疗方案成为临床信赖的治疗手段。CS32582 的 I 期剂量爬坡正按计划进行中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300032494.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","688321","BK0239","BK0188","601555","BK0183","BK0276","BK0028","BK0009"],"gpt_icon":0},{"id":"2461851289","title":"【机构调研记录】金鹰基金调研微芯生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2461851289","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461851289?lang=zh_cn&edition=full","pubTime":"2024-08-21 08:02","pubTimestamp":1724198539,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及8月20日披露的机构调研信息,金鹰基金近期对1家上市公司进行了调研,相关名单如下:1)微芯生物 个股亮点:微芯转债于2022-07-28上市;公司为患者提供可承受的、临床亟需的原创新分子实体药物金鹰基金成立于2002年,截至目前,资产管理规模595.91亿元,排名77/206;资产管理规模345.98亿元,排名86/206;管理公募基金数127只,排名53/206;旗下公募基金经理22人,排名60/206。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100008028.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2461385179","title":"【机构调研记录】财通基金调研微芯生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2461385179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461385179?lang=zh_cn&edition=full","pubTime":"2024-08-21 08:02","pubTimestamp":1724198538,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及8月20日披露的机构调研信息,财通基金近期对1家上市公司进行了调研,相关名单如下:1)微芯生物 个股亮点:微芯转债于2022-07-28上市;公司为患者提供可承受的、临床亟需的原创新分子实体药物财通基金成立于2011年,截至目前,资产管理规模920.23亿元,排名63/206;资产管理规模703.26亿元,排名60/206;管理公募基金数92只,排名69/206;旗下公募基金经理16人,排名82/206。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100008027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2461851410","title":"【机构调研记录】西部利得基金调研中宠股份、微芯生物等4只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2461851410","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461851410?lang=zh_cn&edition=full","pubTime":"2024-08-21 08:02","pubTimestamp":1724198535,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及8月20日披露的机构调研信息,西部利得基金近期对4家上市公司进行了调研,相关名单如下:1)中宠股份 个股亮点:中宠转2于2022-11-21上市;公司生产、加工宠物食品,并销售公司上述所列自产产品;销售宠物饲料添加剂产品。西部利得基金成立于2010年,截至目前,资产管理规模870.88亿元,排名66/206;资产管理规模737.01亿元,排名57/206;管理公募基金数130只,排名52/206;旗下公募基金经理29人,排名41/206。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100008021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321","LU2460026573.USD","002891"],"gpt_icon":0},{"id":"2461851423","title":"【机构调研记录】浙商基金调研图南股份、微芯生物等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2461851423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461851423?lang=zh_cn&edition=full","pubTime":"2024-08-21 08:02","pubTimestamp":1724198530,"startTime":"0","endTime":"0","summary":";公司拟投资2亿元用于柔性显示材料研发中心项目,推进年产1000吨柔性显示基板材料;公司有柔性OLED基板材料的产业化项目浙商基金成立于2010年,截至目前,资产管理规模522.01亿元,排名82/206;资产管理规模350.26亿元,排名85/206;管理公募基金数72只,排名78/206;旗下公募基金经理16人,排名82/206。旗下最近一年表现最佳的公募基金产品为浙商中短债A,最新单位净值为1.14,近一年增长7.18%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100008011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0233","BK0239","300855"],"gpt_icon":0},{"id":"2461517588","title":"【机构调研记录】汇丰晋信基金调研微芯生物、地铁设计等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2461517588","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461517588?lang=zh_cn&edition=full","pubTime":"2024-08-21 08:02","pubTimestamp":1724198526,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及8月20日披露的机构调研信息,汇丰晋信基金近期对3家上市公司进行了调研,相关名单如下:1)微芯生物 (汇丰晋信基金参与公司线上会议)个股亮点:微芯转债(118012)于2022-07-28上市;公司为患者提供可承受的、临床亟需的原创新分子实体药物2)地铁设计 (汇丰晋信基金参与公司电话会议)个股亮点:公司全资子公司科慧能源拥有城市轨道交通高效空调系统关键技术、 轨道","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100008005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321","BK0221","003013"],"gpt_icon":0},{"id":"2461514038","title":"【机构调研记录】易米基金调研海泰新光、微芯生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2461514038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461514038?lang=zh_cn&edition=full","pubTime":"2024-08-21 08:02","pubTimestamp":1724198522,"startTime":"0","endTime":"0","summary":"2)微芯生物 个股亮点:微芯转债于2022-07-28上市;公司为患者提供可承受的、临床亟需的原创新分子实体药物易米基金成立于2017年,截至目前,资产管理规模8.21亿元,排名181/206;资产管理规模8.2亿元,排名168/206;管理公募基金数18只,排名135/206;旗下公募基金经理6人,排名135/206。旗下最近一年表现最佳的公募基金产品为易米和丰债券A,最新单位净值为1.41,近一年增长1.33%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100008001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0251","688677","688321"],"gpt_icon":0},{"id":"2461851470","title":"【机构调研记录】博远基金调研微芯生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2461851470","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461851470?lang=zh_cn&edition=full","pubTime":"2024-08-21 08:01","pubTimestamp":1724198494,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及8月20日披露的机构调研信息,博远基金近期对1家上市公司进行了调研,相关名单如下:1)微芯生物 个股亮点:微芯转债于2022-07-28上市;公司为患者提供可承受的、临床亟需的原创新分子实体药物博远基金成立于2018年,截至目前,资产管理规模174.73亿元,排名122/206;资产管理规模174.73亿元,排名108/206;管理公募基金数17只,排名141/206;旗下公募基金经理5人,排名142/206。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100007964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2461413851","title":"【机构调研记录】华夏基金调研微芯生物、思瑞浦等8只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2461413851","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461413851?lang=zh_cn&edition=full","pubTime":"2024-08-21 08:01","pubTimestamp":1724198488,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及8月20日披露的机构调研信息,华夏基金近期对8家上市公司进行了调研,相关名单如下:1)微芯生物 个股亮点:微芯转债于2022-07-28上市;公司为患者提供可承受的、临床亟需的原创新分子实体药物2)思瑞浦 个股亮点:公司是国内信号链模拟芯片龙头,主要产品包括线性产品、转换器、接口产品等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100007958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0231","BK0239","688321","688536"],"gpt_icon":0},{"id":"2461851425","title":"【机构调研记录】前海联合调研微芯生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2461851425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461851425?lang=zh_cn&edition=full","pubTime":"2024-08-21 08:01","pubTimestamp":1724198486,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及8月20日披露的机构调研信息,前海联合近期对1家上市公司进行了调研,相关名单如下:1)微芯生物 个股亮点:微芯转债于2022-07-28上市;公司为患者提供可承受的、临床亟需的原创新分子实体药物前海联合成立于2015年,截至目前,资产管理规模101.19亿元,排名140/206;资产管理规模91.79亿元,排名122/206;管理公募基金数49只,排名97/206;旗下公募基金经理13人,排名91/206。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100007954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2461512868","title":"【机构调研记录】前海开源基金调研海泰新光、微芯生物等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2461512868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461512868?lang=zh_cn&edition=full","pubTime":"2024-08-21 08:01","pubTimestamp":1724198486,"startTime":"0","endTime":"0","summary":"前海开源基金成立于2013年,截至目前,资产管理规模949.01亿元,排名61/206;资产管理规模788.51亿元,排名54/206;管理公募基金数159只,排名41/206;旗下公募基金经理34人,排名34/206。旗下最近一年表现最佳的公募基金产品为前海开源黄金ETF,最新单位净值为5.51,近一年增长24.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100007953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0251","688677","BK0239"],"gpt_icon":0},{"id":"2460702713","title":"微芯生物:8月19日组织现场参观活动,包括知名机构华银精治的多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2460702713","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460702713?lang=zh_cn&edition=full","pubTime":"2024-08-20 17:11","pubTimestamp":1724145114,"startTime":"0","endTime":"0","summary":"该股最近90天内共有4家机构给出评级,买入评级3家,增持评级1家;过去90天内机构目标均价为31.38。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082000028792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2460502926","title":"微芯生物(688321):西达本胺新适应症持续开拓 西格列他钠进入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2460502926","media":"长城证券股份有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460502926?lang=zh_cn&edition=full","pubTime":"2024-08-20 16:21","pubTimestamp":1724142091,"startTime":"0","endTime":"0","summary":"西达本胺新适应症获批,收入保持增长。销售方面,2024H1 西格列他钠销量同比增长396.15%,收入同比增长632.48%。上市产品西达本胺新适应症顺利获批,收入保持稳健增长;西格列他钠进入医保后快速放量,联合用药方案获批有望开拓新需求场景。长期来看,西达本胺、西格列他钠新适应症以及西奥罗尼的国内外临床试验有序进行,CS12192/CS23546/CS32582 等管线正处于临床早期阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082016213395a9ef3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082016213395a9ef3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688321","BK0239"],"gpt_icon":0},{"id":"2460904541","title":"非酒精性脂肪性肝炎(NASH)概念盘中跳水,微芯生物跌3.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460904541","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460904541?lang=zh_cn&edition=full","pubTime":"2024-08-20 13:02","pubTimestamp":1724130172,"startTime":"0","endTime":"0","summary":"08月20日,非酒精性脂肪性肝炎(NASH)概念盘中跳水,截至13点02分,非酒精性脂肪性肝炎(NASH)概念整体指数下跌2.01%,报958.790点。从个股上来看,该概念的成分股中,微芯生物跌3.54%,众生药业、福瑞股份、通化东宝跌幅居前。从资金上来看,截止发稿,非酒精性脂肪性肝炎(NASH)概念主力净流入为-2974.06万,其中康弘药业受到资金热捧,主力净流入1388.18万;拉长时间线来看,该板块近20日主力资金净流入-10.45亿。(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082013025296826d78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024082013025296826d78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2460821776","title":"太平洋:给予微芯生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2460821776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460821776?lang=zh_cn&edition=full","pubTime":"2024-08-19 11:53","pubTimestamp":1724039585,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司谭紫媚,张懿近期对微芯生物进行研究并发布了研究报告《微芯生物:西达本胺稳步增长,西格列他钠高速增长》,本报告对微芯生物给出买入评级,当前股价为17.73元。2024年上半年西格列他钠销量同比增长396.15%,收入同比增长632.48%。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有2家机构给出评级,买入评级2家;过去90天内机构目标均价为28.84。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081900010879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","601099"],"gpt_icon":0},{"id":"2460760335","title":"华福证券给予微芯生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2460760335","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460760335?lang=zh_cn&edition=full","pubTime":"2024-08-18 13:17","pubTimestamp":1723958220,"startTime":"0","endTime":"0","summary":"华福证券08月17日发布研报称,给予微芯生物(688321.SH,最新价:17.37元)买入评级。评级理由主要包括:1)西格列他钠销售持续高增长,费用端降本增效成效显著;2)西达本胺DLBCL适应症已获批,预计2025年开启快速放量期;3)西达本胺结直肠癌3期临床已启动,看好IO+HDAC的疗效确定性。风险提示:产品研发失败的风险、产品销量不及预期的风险 。AI点评:微芯生物近一个月获得1份券商研报关注,买入1家。(文章来源:每日经济新闻)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408181323069f350835&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408181323069f350835&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["161027","688321"],"gpt_icon":0},{"id":"2460767050","title":"华福证券:给予微芯生物买入评级,目标价位33.92元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460767050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460767050?lang=zh_cn&edition=full","pubTime":"2024-08-18 13:15","pubTimestamp":1723958114,"startTime":"0","endTime":"0","summary":"华福证券有限责任公司盛丽华,杨风雨近期对微芯生物进行研究并发布了研究报告《降本增效成效显著,即将迎来DLBCL收获期》,本报告对微芯生物给出买入评级,认为其目标价位为33.92元,当前股价为17.37元,预期上涨幅度为95.28%。最新盈利预测明细如下:该股最近90天内共有2家机构给出评级,买入评级2家;过去90天内机构目标均价为28.84。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081800001262.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","161027"],"gpt_icon":0},{"id":"2460220213","title":"微芯生物(688321)2024年中报简析:增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2460220213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460220213?lang=zh_cn&edition=full","pubTime":"2024-08-17 06:07","pubTimestamp":1723846034,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期微芯生物发布2024年中报。根据财报显示,微芯生物增收不增利。截至本报告期末,公司营业总收入3.02亿元,同比上升25.06%,归母净利润-4100.64万元,同比下降126.34%。应付职工薪酬变动幅度为-36.57%,原因:报告期已支付2023年绩效奖金。联合治疗周期最多为6个周期,每3周为一个治疗周期,每周期第1、4、8、11天早餐后30分钟服用4片西达本胺片,后单药维持治疗24周。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081700011255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"gpt_icon":0},{"id":"2459298357","title":"微芯生物(688321)6月30日股东户数1.95万户,较上期减少7.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459298357","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459298357?lang=zh_cn&edition=full","pubTime":"2024-08-16 17:02","pubTimestamp":1723798932,"startTime":"0","endTime":"0","summary":"证券之星消息,近日微芯生物披露,截至2024年6月30日公司股东户数为1.95万户,较3月31日减少1645.0户,减幅为7.78%。在化学制药行业个股中,微芯生物股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.24万户。从股价来看,2024年3月31日至2024年6月30日,微芯生物区间跌幅为6.83%,在此期间股东户数减少1645.0户,减幅为7.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081600035473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2019-08-12","address":"广东省深圳市南山区西丽街道曙光社区智谷产业园B栋21F-24F","stockEarnings":[{"period":"1week","weight":-0.034},{"period":"1month","weight":0.0207},{"period":"3month","weight":-0.2141},{"period":"6month","weight":-0.0071},{"period":"1year","weight":-0.2051},{"period":"ytd","weight":-0.2355}],"companyName":"深圳微芯生物科技股份有限公司","boardCode":"AI0027","perCapita":"20907股","boardName":"医药制造业","registeredCapital":"40779万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":" 深圳微芯生物科技股份有限公司的主营业务为药物技术开发、相关成果商业应用,主要产品均为自主研究发现与开发的新分子实体且作用机制新颖的原创新药。公司获得2020中国医药工业信息中心颁发的“中国医药新锐创新力量”奖;2020年10月,公司获 得“2020中国化学制药行业成长型优秀企业品牌”与“2020中国化学制药行业抗肿瘤和免疫调节剂类优秀产品品牌”两个奖项。","serverTime":1724659001326,"listedPrice":20.43,"stockholders":"19505人(较上一季度减少7.78%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微芯生物,688321,微芯生物股票,微芯生物股票老虎,微芯生物股票老虎国际,微芯生物行情,微芯生物股票行情,微芯生物股价,微芯生物股市,微芯生物股票价格,微芯生物股票交易,微芯生物股票购买,微芯生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}